Download PDF
Klin Monbl Augenheilkd 2018; 235(05): 603-610
DOI: 10.1055/s-0042-120542
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Skleritis – Fortschritte zur Diagnose und Therapie

Scleritis – Progress in Diagnosis and Therapy
D. Pohlmann
Universitäts-Augenklinik, Charité Campus Virchow-Klinik, Berlin
,
U. Pleyer
Universitäts-Augenklinik, Charité Campus Virchow-Klinik, Berlin
› Author Affiliations
Further Information

Publication History

eingereicht 17 October 2016

akzeptiert 24 October 2016

Publication Date:
13 February 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Skleritis umfasst ein breites Spektrum morphologischer Veränderungen, die häufig im Rahmen systemischer Erkrankungen auftreten. Während die Episkleritis meist unproblematisch verläuft, ist die Skleritis oft durch einen destruierenden Verlauf charakterisiert. Dies führt nicht selten zu visusrelevanten Folgekomplikationen, die sich als ulzerative Keratitis, Uveitis oder sekundäre intraokulare Drucksteigerung präsentieren. Aufgrund der Schwere dieser Entzündungsform und der häufig zugrunde liegenden Grunderkrankungen soll der Fokus des Beitrags auf die differenzialdiagnostischen Überlegungen und die aktuellen therapeutischen Optionen gelegt werden.

Abstract

Inflammation of the sclera includes a wide range of morphological changes, which often occur in association with systemic diseases. While episcleritis is mainly harmless, scleritis often proceeds and is characterised by a destructive course. This may lead to important complications, that present as ulcerative keratitis, uveitis or secondary increases in intraocular pressure. As this form of inflammation is severe and there are often underlying diseases, this contribution focusses on differential diagnosis and current therapeutic approaches.

Schlüsselwörter

Autoimmunerkrankung - Biologikatherapie - Skleritis - Therapie - Immunsuppression

Key words

autoimmune disease - biological therapy - immunosuppression - scleritis - therapy
 

  • Literatur

  • 1 Watson PG. The enigma of Galileoʼs eyesight: some novel observations on Galileo Galileiʼs vision and his progression to blindness. Surv Ophthalmol 2009; 54: 630-640
    CrossrefPubMedGoogle Scholar
  • 2 Akpek EK, Thorne JE, Qazi FA. et al. Evaluation of patients with scleritis for systemic disease. Ophthalmology 2004; 111: 501-506
    CrossrefPubMedGoogle Scholar
  • 3 Sainz de la Maza M, Tauber J, Foster CS. The Sclera. 2nd ed. New York: Springer; 2012
    Google Scholar
  • 4 Raiji VR, Palestine AG, Parver DL. Scleritis and systemic disease association in a community-based referral practice. Am J Ophthalmol 2009; 148: 946-950
    CrossrefPubMedGoogle Scholar
  • 5 Rothschild PR, Pagnoux C, Seror R. et al. Ophthalmologic manifestations of systemic necrotizing vasculitides at diagnosis: a retrospective study of 1286 patients and review of the literature. Semin Arthritis Rheum 2013; 42: 507-514
    CrossrefPubMedGoogle Scholar
  • 6 Jabs DA, Mudun A, Dunn JP. et al. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol 2000; 130: 469-476
    CrossrefPubMedGoogle Scholar
  • 7 Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol 1976; 60: 163-191
    CrossrefPubMedGoogle Scholar
  • 8 McCluskey PJ, Watson PG, Lightman S. et al. Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology 1999; 106: 2380-2386
    CrossrefPubMedGoogle Scholar
  • 9 Hembry RM, Playfair J, Watson PG. et al. Experimental model for scleritis. Arch Ophthalmol 1979; 97: 1337-1340
    CrossrefPubMedGoogle Scholar
  • 10 Usui Y, Parikh J, Goto H. et al. Immunopathology of necrotising scleritis. Br J Ophthalmol 2008; 92: 417-419
    CrossrefPubMedGoogle Scholar
  • 11 Cao JH, Oray M, Foster CS. Rituximab in the treatment of refractory noninfectious scleritis. Am J Ophthalmol 2016; 166: 207-208
    CrossrefPubMedGoogle Scholar
  • 12 De Fidelix TS, Vieira LA, de Freitas D. et al. Biologic therapy for refractory scleritis: a new treatment perspective. Int Ophthalmol 2015; 35: 903-912
    CrossrefPubMedGoogle Scholar
  • 13 Prada J, Noelle B, Baatz H. et al. Tumor necrosis factor alpha and interleukin 6 gene expression in keratocytes from patients with rheumatoid corneal ulcerations. Br J Ophthalmol 2003; 87: 548-550
    CrossrefPubMedGoogle Scholar
  • 14 Riley GP, Harrall RL, Watson PG. et al. Collagenase (MMP-1) and TIMP-1 in destructive corneal disease associated with rheumatoid arthritis. Eye (Lond) 1995; 9: 703-718
    CrossrefPubMedGoogle Scholar
  • 15 Wakefield D, Di Girolamo N, Thurau S. et al. Scleritis: challenges in immunopathogenesis and treatment. Discov Med 2013; 16: 153-157
    PubMedGoogle Scholar
  • 16 Amadi-Obi A, Yu CR, Liu X. et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007; 13: 711-718
    CrossrefPubMedGoogle Scholar
  • 17 Itty S, Pulido JS, Bakri SJ. et al. Anti-cyclic citrullinated peptide, rheumatoid factor, and ocular symptoms typical of rheumatoid arthritis. Trans Am Ophthalmol Soc 2008; 106: 75-81
    PubMedGoogle Scholar
  • 18 OʼDonoghue E, Lightman S, Tuft S. et al. Surgically induced necrotising sclerokeratitis (SINS) – precipitating factors and response to treatment. Br J Ophthalmol 1992; 76: 17-21
    CrossrefPubMedGoogle Scholar
  • 19 Doshi RR, Harocopos GJ, Schwab IR. et al. The spectrum of postoperative scleral necrosis. Surv Ophthalmol 2013; 58: 620-633
    CrossrefPubMedGoogle Scholar
  • 20 Reddy JC, Murthy SI, Reddy AK. et al. Risk factors and clinical outcomes of bacterial and fungal scleritis at a tertiary eye care hospital. Middle East Afr J Ophthalmol 2015; 22: 203-211
    CrossrefPubMedGoogle Scholar
  • 21 Livir-Rallatos C, El-Shabrawi Y, Zatirakis P. et al. Recurrent nodular scleritis associated with varicella zoster virus. Am J Ophthalmol 1998; 126: 594-597
    CrossrefPubMedGoogle Scholar
  • 22 Nieuwenhuizen J, Watson PG, Emmanouilidis-van der Spek K. et al. The value of combining anterior segment fluorescein angiography with indocyanine green angiography in scleral inflammation. Ophthalmology 2003; 110: 1653-1666
    CrossrefPubMedGoogle Scholar
  • 23 Axmann S, Ebneter A, Zinkernagel MS. Imaging of the sclera in patients with scleritis and episcleritis using anterior segment optical coherence tomography. Ocul Immunol Inflamm 2016; 24: 29-34
    CrossrefPubMedGoogle Scholar
  • 24 Levison AL, Lowder CY, Baynes KM. et al. Anterior segment spectral domain optical coherence tomography imaging of patients with anterior scleritis. Int Ophthalmol 2016; 36: 499-508
    CrossrefPubMedGoogle Scholar
  • 25 Pleyer U, Bergmann L, Krause A. et al. [Autoimmune diseases of the peripheral cornea. Immunopathology, clinical aspects and therapy]. Klin Monatsbl Augenheilkd 1998; 208: 73-81
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Silva BL, Cardozo JB, Marback P. et al. Peripheral ulcerative keratitis: a serious complication of rheumatoid arthritis. Rheumatol Int 2010; 30: 1267-1268
    CrossrefPubMedGoogle Scholar
  • 27 Galor A, Thorne JE. Scleritis and peripheral ulcerative keratitis. Rheum Dis Clin North Am 2007; 33: 835-854
    CrossrefPubMedGoogle Scholar
  • 28 Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology 1984; 91: 1253-1263
    CrossrefPubMedGoogle Scholar
  • 29 McCluskey PJ, Watson PG, Lightman S. et al. Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology 2009; 106: 2380-2386
    PubMedGoogle Scholar
  • 30 Heiligenhaus A, Dück N, Michel D. et al. Indikation und Wirksamkeit einer Immunsuppression bei Patienten mit Skleritis. Klin Monatsbl Augenheilkd 2003; 220: 471-480
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Jeon HS, Hyon JY, Kim MK. et al. Efficacy and safety of immunosuppressive agents in the treatment of necrotising scleritis: a retrospective, multicentre study in Korea. Br J Ophthalmol 2016; 100: 1066-1070
    CrossrefPubMedGoogle Scholar
  • 32 Roufas A, Jalaludin B, Gaskin C. et al. Subconjunctival triamcinolone treatment for non-necrotising anterior scleritis. Br J Ophthalmol 2010; 94: 743-747
    CrossrefPubMedGoogle Scholar
  • 33 Sohn EH, Wang R, Read R. et al. Long-term, multicenter evaluation of subconjunctival injection of triamcinolone for non-necrotizing, noninfectious anterior scleritis. Ophthalmology 2011; 118: 1932-1937
    CrossrefPubMedGoogle Scholar
  • 34 Pohlmann D, Winterhalter S, Pleyer U. Intravitreal dexamethasone for the treatment of CMO associated with refractory sclerouveitis. Ocul Immunol Inflamm 2016; DOI: 10.1080/09273948.2016.1196712.
    PubMedGoogle Scholar
  • 35 Pujari SS, Kempen JH, Newcomb CW. et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 2010; 117: 356-365
    CrossrefPubMedGoogle Scholar
  • 36 Restrepo JP, Molina MP. Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol 2010; 29: 559-561
    CrossrefPubMedGoogle Scholar
  • 37 Weiss K, Rieger R, Keitzer R. et al. Successful infliximab treatment of posterior scleritis in a 13-year-old child refractory to other immunosuppressive therapy. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1735-1737
    CrossrefPubMedGoogle Scholar
  • 38 Atchia II, Kidd CE, Bell RW. Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J Clin Rheumatol 2006; 12: 291-293
    CrossrefPubMedGoogle Scholar
  • 39 Cao JH, Oray M, Foster CS. Rituximab in the treatment of refractory noninfectious scleritis. Am J Ophthalmol 2016; 166: 207-208
    CrossrefPubMedGoogle Scholar
  • 40 Chauhan S, Kamal A, Thompson RN. et al. Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br J Ophthalmol 2009; 93: 984-985
    PubMedGoogle Scholar
  • 41 Serna-Ojeda JC, Flores-Suárez LF. Rituximab in the treatment of refractory noninfectious scleritis. Am J Ophthalmol 2016; 166: 207
    CrossrefPubMedGoogle Scholar
  • 42 Botsios C, Sfriso P, Ostuni PA. et al. Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases. Rheumatology (Oxford) 2007; 46: 1042-1043
    CrossrefPubMedGoogle Scholar
  • 43 Pleyer U, Bertelmann E, Rieck P. et al. Outcome of penetrating keratoplasty in rheumatoid arthritis. Ophthalmologica 2002; 216: 249-255
    CrossrefPubMedGoogle Scholar
  • 44 Sainz de la Maza M, Tauber J, Foster CS. Scleral grafting for necrotizing scleritis. Ophthalmology 1989; 96: 306-310
    CrossrefPubMedGoogle Scholar
  • 45 Feist E, Pleyer U. [Diseases of the outer eye in rheumatoid arthritis]. Z Rheumatol 2010; 69: 403-410
    CrossrefPubMedGoogle Scholar
  • 46 Wieringa WG, Wieringa JE, ten Dam-van Loon NH. et al. Visual outcome, treatment results, and prognostic factors in patients with scleritis. Ophthalmology 2013; 120: 379-386
    CrossrefPubMedGoogle Scholar